Insight Molecular Diagnostics Presents GraftAssure Rollout Plans With Seven US Centers in Validation

By Public Technologies
  • Insight Molecular Diagnostics has seven U.S. transplant centers validating GraftAssure, with launches expected in 2027.
  • These centers represent about 7% of annual U.S. kidney transplant volume, supporting an annual revenue target above $15 million at steady state.
  • GraftAssureDx remains under FDA review for commercial use following its March 2026 submission.
  • Medicare reimbursement for GraftAssureCore is $2,753 per result, supporting the strategy to move transplant testing into local laboratories.
  • Bio-Rad is a top-five shareholder following four equity investments; GraftAssure assays run on its instruments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.